Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib

A reduction in BCR-ABL1/ABL1(IS) transcript levels to <10% after 3 months or <1% after 6 months of tyrosine kinase inhibitor therapy are associated with superior clinical outcomes in chronic myeloid leukemia (CML) patients. In this study, we investigated the reliability of multiple BCR-ABL1 th...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int J Mol Sci
Egile Nagusiak: Stella, Stefania, Zammit, Valentina, Vitale, Silvia Rita, Pennisi, Maria Stella, Massimino, Michele, Tirrò, Elena, Forte, Stefano, Spitaleri, Antonio, Antolino, Agostino, Siragusa, Sergio, Accurso, Vincenzo, Mannina, Donato, Impera, Stefana, Musolino, Caterina, Russo, Sabina, Malato, Alessandra, Mineo, Giuseppe, Musso, Maurizio, Porretto, Ferdinando, Martino, Bruno, Di Raimondo, Francesco, Manzella, Livia, Vigneri, Paolo, Stagno, Fabio
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6539817/
https://ncbi.nlm.nih.gov/pubmed/31064152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms20092226
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak